This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
​​​​​​​Downloadable ResourcesAboutAboutMechanism of ActionGuidelinesClinical Efficacy  Clinical Efficacy ARCHER 1050: Study DesignEfficacy (PFS) in the ITT PopulationEfficacy (PFS) in the Asian PopulationEfficacy (ORR and DoR)Efficacy (mOS)

Menu

Close

Dosing & Therapy ManagementDosing & Therapy ManagementDosageDose ModificationsProactive Management of Adverse EventsEfficacy Maintained After Dose ReductionSafety ProfileSupport & Services Support & Services Prescribing Information​​​​​​​Downloadable ResourcesEvents & WebinarsVideosLatest ArticlesExplore materialsExplore Videos

Start With Proven First-line Efficacy1-3
 

Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.3

Dose Modifications

DACOPLICE® dose modifications: Diarrhoea3


Severe and fatal diarrhea occurred in patients treated with DACOPLICE®. Diarrhea occurred in 86% of the 394 DACOPLICE®-treated patients; Grade 3 or 4 diarrhea was reported in 11% of patients and 0.3% of cases were fatal.3 
 

Recommendations include3:

  • Patients should contact their healthcare provider at the first sign of diarrhoea

  • Patient may require intravenous hydration and/or anti-diarrhoeal medication to manage diarrhoea

DACOPLICE® dose modifications: Dermatological effects3

  • Rash and exfoliative skin reactions occurred in patients treated with DACOPLICE®3

  • The incidence and severity of rash and exfoliative skin reactions may increase with sun exposure3

Recommendations include3: 


Advise patients to initiate the use of moisturizers and to minimise sun exposure with protective clothing and the use of sunscreen at the time of the initiation of DACOPLICE®. Advise patients to contact their healthcare provider immediately to report new or worsening rash, erythematous and exfoliative reaction.3

 

DACOPLICE® dose modifications: ILD/pneumonitis3
 

Severe and fatal ILD/pneumonitis occurred in patients treated with DACOPLICE® and occurred
in 0.5% of the 394 DACOPLICE®-treated patients; 0.3% of cases were fatal.

Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Withhold DACOPLICE®
and promptly investigate for ILD in patients who present with worsening of respiratory
symptoms which may be indicative of ILD (e.g. dyspnoea, cough and fever). Permanently
discontinue DACOPLICE® if ILD is confirmed.

  

  

ILD, interstitial lung disease.

  

References:

Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466.Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244-2250.Dacoplice. Local product document. Pfizer; 2021. Version LPDDAC042021.

     

Please click the Prescribing Information link to view the safety and adverse events information of DACOPLICE®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

     

PP-DAC-IND-0147 June 2022
Dosing & Therapy Management
Mechanism of Action

DACOPLICE® is a second-generation EGFR TKI​​​​

Learn more


Clinical Efficacy

First-line use of DACOPLICE® was studied in a Phase III, head-to-head trial with gefitinib

Review efficacy profile


Safety Profile

ARCHER 1050 study reported the most common adverse events in patients

Review safety profile
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-DAC-IND-0147

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​